1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.3109/09546634.2013.782095" target="_blank" rel="noreferrer noopener">http://doi.org/10.3109/09546634.2013.782095</a>
Pages
63–66
Issue
1
Volume
25
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Concurrent treatment of chronic psoriasis and asthma with ustekinumab.
Publisher
An entity responsible for making the resource available
The Journal of dermatological treatment
Date
A point or period of time associated with an event in the lifecycle of the resource
2014
2014-02
Subject
The topic of the resource
Female; Humans; Middle Aged; Chronic Disease; Asthma/*drug therapy; Immunosuppressive Agents/metabolism/*therapeutic use; Inflammation/drug therapy; Interleukin-12/metabolism; Interleukin-23/metabolism; Psoriasis/*drug therapy; Ustekinumab; Antibodies; Injections; Subcutaneous; Monoclonal; Humanized/metabolism/*therapeutic use; Monoclonal/administration & dosage/immunology/therapeutic use
Creator
An entity primarily responsible for making the resource
Amarnani Ajay; Rosenthal Ken S; Mercado Jorge M; Brodell Robert T
Description
An account of the resource
A 56-year-old woman with a 40-year history of guttate flares of psoriasis associated with stress and infection as well as chronic asthma was treated with subcutaneous injections of ustekinumab, repeated after 1 month and then every 3 months. Her psoriasis completely resolved, and her capacity for exercise was markedly increased and asthma maintenance medications were no longer needed. Ustekinumab is a human monoclonal antibody that binds the p40 subunit of IL-12 and IL-23 to limit the progression of the Th1 and Th17 inflammatory immune responses that maintain many autoimmune and inflammatory diseases. Th17-related responses drive inflammation during late stages of chronic asthma and can also be blocked by ustekinumab. Blocking the underlying cytokine-mediated inflammatory responses for psoriasis with ustekinumab can also treat other chronic inflammatory diseases.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.3109/09546634.2013.782095" target="_blank" rel="noreferrer noopener">10.3109/09546634.2013.782095</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2014
Amarnani Ajay
Antibodies
Asthma/*drug therapy
Brodell Robert T
Chronic Disease
Female
Humanized/metabolism/*therapeutic use
Humans
Immunosuppressive Agents/metabolism/*therapeutic use
Inflammation/drug therapy
Injections
Interleukin-12/metabolism
Interleukin-23/metabolism
Mercado Jorge M
Middle Aged
Monoclonal
Monoclonal/administration & dosage/immunology/therapeutic use
Psoriasis/*drug therapy
Rosenthal Ken S
Subcutaneous
The Journal of dermatological treatment
Ustekinumab